Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Gerrits

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|December 15, 1990
[Evaluation of the roentgenological and endoscopic diagnosis in malignities of the proximal digestive tract]C J Gerrits, J H Enneking, R W de Koning
British Journal of Cancer|January 1, 1997
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical developmentC J Gerrits, M J de Jonge, J H Schellens, et al.
British Journal of Haematology|November 1, 1994
Ultrasound examination of pathological cervical lymph nodes in patients with non-Hodgkin's lymphoma and Hodgkin's diseaseC J Gerrits, H van Overhagen, K van Lom, et al.
British Journal of Cancer|January 1, 1997
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorC J Gerrits, J H Schellens, G J Creemers, et al.
British Journal of Haematology|April 1, 1996
Somatostatin receptor scintigraphy in the initial staging of Hodgkin's diseaseP J van den Anker-Lugtenburg, E P Krenning, H Y Oei, et al.
British Journal of Cancer|March 1, 1996
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationC J Gerrits, G J Creemers, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancerG J Creemers, C J Gerrits, J H Schellens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nederlands Tijdschrift Voor Geneeskunde|December 15, 1990
[Evaluation of the roentgenological and endoscopic diagnosis in malignities of the proximal digestive tract]C J Gerrits, J H Enneking, R W de Koning
British Journal of Cancer|January 1, 1997
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical developmentC J Gerrits, M J de Jonge, J H Schellens, et al.
British Journal of Haematology|November 1, 1994
Ultrasound examination of pathological cervical lymph nodes in patients with non-Hodgkin's lymphoma and Hodgkin's diseaseC J Gerrits, H van Overhagen, K van Lom, et al.
British Journal of Cancer|January 1, 1997
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorC J Gerrits, J H Schellens, G J Creemers, et al.
British Journal of Haematology|April 1, 1996
Somatostatin receptor scintigraphy in the initial staging of Hodgkin's diseaseP J van den Anker-Lugtenburg, E P Krenning, H Y Oei, et al.
British Journal of Cancer|March 1, 1996
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationC J Gerrits, G J Creemers, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancerG J Creemers, C J Gerrits, J H Schellens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
Pageof 2